The affordability applications are truly worth watching. Novo Nordisk’s financial savings plans may well evolve as Opposition heats up.The Norwegian Medicines Agency explained in January 2023 it wouldn't subsidise the drug, declaring the price might be much too high in relation towards the documented health consequences.This source squeeze could